NCT01954589View on ClinicalTrials.gov

Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
SafetyTolerabilityPharmacodynamicsPharmacokinetics
Interventions
DRUG

ACT-462206 5 mg

DRUG

ACT-462206 25 mg

DRUG

ACT-462206 100mg

DRUG

ACT-462206 200mg

DRUG

ACT-462206 400mg

DRUG

ACT-462206 1000 mg

DRUG

ACT-462206 1500mg

DRUG

Almorexant 400mg

DRUG

Placebo

Trial Locations (1)

2333 CL

Centre for Human Drug Research, Leiden

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY